Subscribe
Home
Issues
2026
February 2026 - Vol 19 No 1
2025
November 2025 - Vol 18 No 4
August 2025 - Vol 18 No 3
May 2025 - Vol 18 No 2
February 2025 - Vol 18 No 1
2024
November 2024 - Vol 17 No 4
September 2024 - Vol 17 No 3
May 2024 - Vol 17 No 2
February 2024 - Vol 17 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ASCO 2025 - Small Cell Lung Cancer
ONS 2025 - Endometrial Cancer
Web Exclusives
Case-Based Exchanges
Evolving Landscapes in Multiple Myeloma
OFS Summit
Drug Updates
Videos
Interview with the Innovators
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Master Class Series
Ask the Experts
Advanced Endometrial Cancer Education
Resources
Quick Quiz
Articles
Articles
New Studies Provide Insights into Cognitive Impairments in Cancer Patients
TON - Daily
Although commonly referred to as “chemobrain” and described most often in women with breast cancer, cognitive impairments may occur in patients with other types of cancer and after hormonal and radiation therapies as well, a new study suggests. Another recent study was the first to use imaging to show changes in brain tissue in women undergoing chemotherapy.
Read More ›
Combination of Agents Show Promise as First-line Therapy for Metastatic Breast Cancer
TON - Daily
Preliminary results of an ongoing trial suggest that a combination of trastuzumab, bevacizumab, and docetaxel is safe and effective as first-line therapy in women with metastatic breast cancer (MBC).
Fourteen of the 18 patients treated to date had a partial response or stable disease, a clinical benefit rate of 77.7, the investigators report.
Read More ›
Adding Rituximab to Chemotherapy Increases Survival in CLL
TON - Daily
Adding the monoclonal antibody rituximab to chemotherapy signicantly increases both progression-free and overall survival in previously untreated patients with chronic lymphocytic leukemia (CLL), the German Lymphocytic Leukemia Study Group reports.
Read More ›
New Taxane Improves Survival in Men with Castration-resistant Prostate Cancer
TON - Daily
The recently approved taxane cabazitaxel significantly improved overall survival in men with castration-resistant prostate cancer in a multinational phase 3 study.
The TROPIC investigators found that men treated with cabazitaxel plus prednisone had 30% lower risk of death compared with patients treated with mitoxantrone plus prednisone.
Read More ›
Reduced Chemo Safe and Effective for Childhood Neuroblastoma
TON - Daily
Results of a trial by the Children's Oncology Group indicate that children with intermediate-risk neuroblastoma can be successfully treated with a shorter duration and lower doses of chemotherapy than are currently used.
Findings from the phase 3 trial reported in the September 30, 2010, issue of the
New England Journal of Medicine
may change the approach to treating the disease, which affects 650 children in the United States each year.
Read More ›
Surgery Proved Effective for High-risk Prostate Cancer
TON - Daily
Surgery provides excellent long-term cancer control and high survival rates for men with aggressive prostate cancer, a new study suggests.
In the study by researchers from the Mayo Clinic, Rochester, Minnesota, and Fox Chase Cancer Center, Philadelphia, men with high-risk prostate cancer who underwent radical prostatectomy had a 10-year cancer-specific survival rate of 92% and an overall survival rate of 77%.
Read More ›
Study Supports Early Referral of Young Cancer Patients for Fertility Preservation
TON - Daily
Findings of a new study demonstrate the benefit of early referral of young women with breast cancer to reproductive specialists for fertility preservation.
The study, reported online September 27 in the
Journal of Clinical Oncology
, showed that referral to reproductive specialists before breast surgery increases the likelihood of obtaining a sufficient number of oocytes for fertility preservation without delaying breast cancer treatment.
Read More ›
Male Partners of Breast Cancer Patients at Increased Risk for Mood Disorders
TON - Daily
Findings of a large new study point to the potentially devastating impact of a cancer diagnosis on the mental health of a patient’s partner and the importance of involving family members in treatment.
The study of Danish men showed that men whose partners were diagnosed with breast cancer were significantly more likely to be hospitalized with an affective disorder than men whose partners did not have breast cancer. The results are reported in the September 27 online edition of
Cancer
.
Read More ›
Breast Cancer Survivors with Functional Limitations Have Poor Prognosis
Hematologic Cancers
TON - Daily
Women who have difficulty performing normal activities of daily living after an initial treatment for breast cancer have reduced overall survival compared with survivors without functional limitations, results of a long-term study indicate.
“Our study provides evidence of why it is important to develop interventions that improve physical function, to mitigate the adverse effects of physical limitations,” said lead author Dejana Braithwaite, PhD, of the University of California San Francisco.
Read More ›
Dexrazoxane Has Long-term Cardioprotective Effects in Childhood ALL Survivors
TON - Daily
Dexrazoxane provides long-term protection against against doxorubicin-induced heart damage in survivors of childhood high-risk acute lymphoblastic leukemia (ALL) and does not compromise oncologic efficacy, a new multicenter study indicates.
Read More ›
Page 364 of 376
361
362
363
364
365
366
367
View the Latest Issue of TON
Read Issue
Home
Issues
2026
February 2026 - Vol 19 No 1
2025
November 2025 - Vol 18 No 4
August 2025 - Vol 18 No 3
May 2025 - Vol 18 No 2
February 2025 - Vol 18 No 1
2024
November 2024 - Vol 17 No 4
September 2024 - Vol 17 No 3
May 2024 - Vol 17 No 2
February 2024 - Vol 17 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ASCO 2025 - Small Cell Lung Cancer
ONS 2025 - Endometrial Cancer
Web Exclusives
Case-Based Exchanges
Evolving Landscapes in Multiple Myeloma
OFS Summit
Drug Updates
Videos
Interview with the Innovators
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Master Class Series
Ask the Experts
Advanced Endometrial Cancer Education
Resources
Quick Quiz
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Vietnam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION